Lanna Caterina, Rivieccio Antonia, Vultaggio Martina, Gaeta Shumak Ruslana, Bonacci Francesco Maria, Artosi Fabio, Borselli Cristiana, Costanza Gaetana, Bianchi Luca, Campione Elena
Dermatology Unit, Department of Systems Medicine, Università di Roma Tor Vergata, Roma, Italia.
Virology Unit, Department of Experimental Medicine, Università di Roma Tor Vergata, Roma, Italia.
Clin Cosmet Investig Dermatol. 2025 May 20;18:1231-1238. doi: 10.2147/CCID.S499658. eCollection 2025.
Psoriasis and psoriatic arthritis are chronic autoimmune inflammatory conditions frequently associated with a range of comorbidities, including oncological diseases. Managing these conditions in patients with a history of cancer requires careful consideration of treatment efficacy and safety. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, has shown promise in the treatment of psoriasis and psoriatic arthritis. However, data on its use in oncological patients remain limited.
This retrospective observational study evaluated the efficacy and safety of Apremilast in 79 patients with a history of cancer who were treated for psoriasis and/or psoriatic arthritis over a period of approximately five years. Clinical outcomes were assessed using the Psoriasis Area Severity Index (PASI), Dermatology Life Quality Index (DLQI), and Visual Analog Scale for pain (PAIN VAS) to monitor disease severity, quality of life, and articular involvement, respectively. Regular oncological assessments were conducted concurrently with Apremilast therapy to ensure patient safety and identify potential interactions.
Over the five-year treatment period, significant improvements were observed in PASI, DLQI, and PAIN VAS scores, indicating effective management of both dermatological and articular symptoms. Patients reported enhanced quality of life and reduced pain levels, reflecting the therapeutic benefits of Apremilast. Oncological evaluations revealed no significant adverse interactions between Apremilast and the patients' cancer history or treatments, underscoring the drug's safety profile in this population.
This study highlights the efficacy and safety of Apremilast as a treatment option for psoriasis and psoriatic arthritis in oncological patients. The findings support its role in improving disease outcomes and quality of life, emphasizing the importance of personalized treatment strategies in managing complex cases involving a history of cancer. Further research is warranted to validate these results in larger patient cohorts.
银屑病和银屑病关节炎是慢性自身免疫性炎症性疾病，常与一系列合并症相关，包括肿瘤性疾病。在有癌症病史的患者中管理这些疾病需要仔细考虑治疗效果和安全性。阿普米司特是一种口服磷酸二酯酶4（PDE4）抑制剂，已显示出在治疗银屑病和银屑病关节炎方面的前景。然而，其在肿瘤患者中的使用数据仍然有限。
这项回顾性观察性研究评估了阿普米司特在79例有癌症病史的患者中的疗效和安全性，这些患者在大约五年的时间里接受了银屑病和/或银屑病关节炎的治疗。使用银屑病面积和严重程度指数（PASI）、皮肤病生活质量指数（DLQI）和疼痛视觉模拟量表（PAIN VAS）分别评估临床结局，以监测疾病严重程度、生活质量和关节受累情况。在阿普米司特治疗的同时进行定期肿瘤学评估，以确保患者安全并识别潜在的相互作用。
在五年的治疗期间，观察到PASI、DLQI和PAIN VAS评分有显著改善，表明皮肤和关节症状均得到有效管理。患者报告生活质量提高，疼痛水平降低，反映了阿普米司特的治疗益处。肿瘤学评估显示，阿普米司特与患者的癌症病史或治疗之间没有显著的不良相互作用，强调了该药物在这一人群中的安全性。
本研究强调了阿普米司特作为肿瘤患者银屑病和银屑病关节炎治疗选择的疗效和安全性。这些发现支持其在改善疾病结局和生活质量方面的作用，强调了个性化治疗策略在管理涉及癌症病史的复杂病例中的重要性。有必要进行进一步研究以在更大的患者队列中验证这些结果。
